Weekly Funding Opportunities

[Med Research]

National Institute of Standards and Technology: Precision Measurement Grant Program (PMGP)<https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=330872__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hlrK8UUs$ > – see attached notice of funding opportunity
The PMGP is seeking applications to support significant research in the field of fundamental measurement or the determination of fundamental constants. See Bioscience Topic Area<https://urldefense.com/v3/__https://www.nist.gov/laboratories/projects-programs?k=&a*5B*5D=248321&tag=__;JSU!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h_SsPVR8$ > for examples of projects/programs of interest. Notice of Funding Opportunity attached.
Abbreviated applications (~5 double spaced pages) due February 17, 2021. Med-RA deadline to receive draft documents: February 4.

Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-21-110.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hD5IrGwg$ >
The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.
Due February 16, 2021; June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; and October 16, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 3.

Pediatric Cancer Research Foundation: Research Grants<https://urldefense.com/v3/__https://pcrf-kids.org/grants-2/__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h1TKwUp0$ >
The Pediatric Cancer Research Foundation awards three types of grants:

  *   Emerging Investigator Fellowship Grants: $50,000 / year; can be renewed annually
  *   Translational Research Grants: multi-year; $100,000 / year
  *   Basic Science Grants: multi-year; $250,000 / year
Letter of intent due March 1, 2021. Med-RA deadline to receive draft documents: February 16.

Foundation for Prader-Willi Research<https://urldefense.com/v3/__https://www.fpwr.org/request-for-applications__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hSxhElFU$ >
The Foundation for Prader-Willi Research addresses the many issues related to Prader-Willi Syndrome, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS. Funding priorities include:

  *   Genotype to phenotype: understanding PWS genetics / how loss of PWS-critical region genes leads to the phenotype
  *   Neurobiology of hunger / feeding behavior in PWS
  *   Neurobiology of cognitive deficits, maladaptive behavior and mental illness in PWS
  *   Clinical care research: evaluation of existing drugs and interventions to improve health and quality of life in PWS
  *   Therapeutics development for PWS- Genetic therapies; novel pharmaceuticals; drug repurposing for PWS
One-year projects; $100,000; 8% IDC.
Letter of intent due March 5, 2021. Med-RA deadline to receive draft documents: February 22.

Cellular Senescence Network: Technology Development and Application (UG3 / UH3 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-009.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hPWrDUiU$ >
The purpose of this Funding Opportunity Announcement (FOA) is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.
Due March 8, 2021. Med-RA deadline to receive draft documents: February 23.

Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer’s Disease (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-033.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hfbaYHeI$ >
This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer’s disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD.
Due March 18, 2021. Med-RA deadline to receive draft documents: March 8.

HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-145.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hQzzGf7A$ >
In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative<https://urldefense.com/v3/__https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hcWsCYmc$ >, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. In response to this initiative, the National Institute of Mental Health (NIMH), in partnership with other NIH Institutes, Centers, and Offices, invites research that will optimize multi-component service delivery interventions for people with opioid use disorder (OUD) and co-occurring conditions, to include mental disorders and/or suicide risk. The purpose of the initiative is to support studies that will (1) test the overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions.
Due March 18, 2021. Med-RA deadline to receive draft documents: March 8.

HEAL Initiative: HEALthy Brain and Child Development Study (U01 / Collaborative U01 – Clinical Trial Not Allowed)
U01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hNmf1k-8$ >
Collaborative U01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hcsZMG54$ >
The purpose of these Funding Opportunity Announcements (FOAs) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. These FOAs seek applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.
Due March 31, 2021. Med-RA deadline to receive draft documents: March 18.

Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-21-031.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hDjJ3R9Q$ >
This Funding Opportunity Announcement seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for May 5 standard date: April 22.

Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-20-121.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hS9muP_8$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV).
Standard dates apply. Expires January 8, 2022. Med-RA deadline to receive draft documents for May 7 standard date: April 26.

NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h1ExGtP4$ >
This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute.
Due May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; and May 12, 2023. Med-RA deadline to receive draft documents for May 2021 due date: April 29.

NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-083.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h5Alzsqo$ >
This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities.
Due May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022; September 13, 2022; January 13, 2023; May 13, 2023; September 14, 2023; and January 13, 2024. Med-RA deadline to receive draft documents for May 2021 due date: May 3.

Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-077.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h68bRp-4$ >
The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.
Due June 4, 2021. Med-RA deadline to receive draft documents: May 24.

EMDR Foundation Research Grants<https://urldefense.com/v3/__https://emdrresearchfoundation.org/research-grants/25000-emdr-research-grant-award/__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hLDPxDag$ >
Grant awards of up to $25,000 are available for post-doctoral students, university faculty, or clinicians conducting research on Eye Movement Desensitization and Reprocessing (EMDR). Current research priorities include:
1st Priority – Advancing Evidence Based Practice: Increase the availability of quality EMDR research in areas where we already have a foot-hold in the literature but where more evidence is needed. Specifically, those areas are in the use of EMDR therapy to treat:

  *   Anxiety
  *   Depression
  *   Military PTSD
  *   Phantom Limb Pain
  *   To enhance recovery from the impact of cardiac events and the diagnosis and treatment of cancer
2nd Priority – Addressing the Global Burden of Trauma: Investigate the use of EMDR in natural or man-made disaster responses, by determining the effectiveness of the following protocols: early intervention protocols, the child or adult group protocols, or the use of EMDR standard protocols in disaster response.
3rd Priority – Building Clinical Evidence: There are a number of areas where EMDR therapy is being used, clinical observations are positive, and there are some research indicators of success. However, more research is needed to build a body of literature in these populations or diagnostic categories, including but not limited to:

  *   Addictions
  *   Eating disorders
  *   Dissociative disorders
  *   Additional medical/somatic conditions
  *   Suicide prevention and/or to address the impact of suicide
These priorities apply to research across the lifespan.
Due July 1, 2021. Med-RA deadline to receive draft documents: June 21.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210115/7c8d69a8/attachment.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: 2021-NIST-PMGP-01 NOFO.pdf
Type: application/pdf
Size: 333011 bytes
Desc: 2021-NIST-PMGP-01 NOFO.pdf
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210115/7c8d69a8/attachment.pdf>